within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AC02_Tenoxicam;

model Tenoxicam_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.1666666666666667e-07,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.012,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0064,
    k12 = 1.0555555555555557e-07,
    k21 = 1.0555555555555557e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tenoxicam_1</td></tr><tr><td>ATC code:</td><td>M01AC02_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>12.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.42</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. It is primarily used for the treatment of pain and inflammation in musculoskeletal and joint disorders such as rheumatoid arthritis and osteoarthritis. It is approved for clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy volunteers after intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01AC02_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tenoxicam_1;
